MANLEY PAUL W has a total of 21 patent applications. Its first patent ever was published in 2006. It filed its patents most often in United States and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets pharmaceuticals and organic fine chemistry are POXEL SAS, NEUROGASTRX INC and IMPACT BIOMEDICINES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 19 | |
#2 | WIPO (World Intellectual Property Organization) | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Heterocyclic compounds |
# | Name | Total Patents |
---|---|---|
#1 | Manley Paul W | 21 |
#2 | Sutton Paul Allen | 4 |
#3 | Shieh Wen-Chung | 4 |
#4 | Brozio Joerg | 3 |
#5 | Karpinski Piotr H | 3 |
#6 | Wu Raeann | 3 |
#7 | Bhalla Kapil N | 2 |
#8 | Martiny-Baron Georg | 2 |
#9 | Monnier Stephanie | 2 |
#10 | Roesel Johannes | 2 |
Publication | Filing date | Title |
---|---|---|
US2010022569A1 | 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma | |
US2010152198A1 | Use of c-src inhibitors in combination with a pyrimidylaminobenzamide compound for the treatment of leukemia | |
US2008255171A1 | Combination of Nilotinib with Farnesyl Transferase Inhibitors | |
US2008200488A1 | Combinations Comprising a Protein Kinase Inhibitor Being a Pyrimidylaminobenzamide Compound and a Hsp90 Inhibitor Such as 17-Aag | |
US2008114001A1 | Use of Pyrimidylaminobenzamides for the Treatment of Diseases that Respond to Modulation of Tie-2 Kinase Activity |